Levamisole

Levamisole
Clinical data
Trade names	Decaris, Ergamisol
AHFS/Drugs.com	Micromedex Detailed Consumer Information
MedlinePlus	a697011
License data	US DailyMed: Levamisole;
Routes of; administration	By mouth
ATC code	P02CE01 (WHO) QP52AE01 (WHO);
Legal status
Legal status	CA: Withdrawn; US: Withdrawn; Rx-only (RU);
Pharmacokinetic data
Metabolism	Liver
Elimination half-life	3–4 hours
Excretion	Kidney (70%)
Identifiers
	IUPAC name (S)-6-Phenyl-2,3,5,6-tetrahydroimidazo[2,1-b] [1,3]thiazole;
CAS Number	14769-73-4 ;
PubChem CID	26879;
IUPHAR/BPS	7210;
DrugBank	DB00848 ;
ChemSpider	25037 ;
UNII	2880D3468G;
KEGG	D08114 ;
ChEBI	CHEBI:6432 ;
ChEMBL	ChEMBL1454 ;
CompTox Dashboard (EPA)	DTXSID4023206 ;
ECHA InfoCard	100.035.290
Chemical and physical data
Formula	C11H12N2S
Molar mass	204.29 g·mol−1
3D model (JSmol)	Interactive image;
Density	1.31 g/cm3
Melting point	60 °C (140 °F)
Solubility in water	hydrochloride: 210 mg/mL (20 °C)
	SMILES N\2=C1/SCCN1C[C@@H]/2c3ccccc3;
	InChI InChI=1S/C11H12N2S/c1-2-4-9(5-3-1)10-8-13-6-7-14-11(13)12-10/h1-5,10H,6-8H2/t10-/m1/s1 ; Key:HLFSDGLLUJUHTE-SNVBAGLBSA-N ;
	(what is this?) (verify)

Levamisole, sold under the brand name Ergamisol among others, is a medication used to treat parasitic worm infections, specifically ascariasis and hookworm infections. It is taken by mouth.

Side effects may include abdominal pain, vomiting, headache, and dizziness. Use is not recommended during breastfeeding or the third trimester of pregnancy. Serious side effects may include an increased risk of infection. It belongs to the anthelmintic class of medications.

Levamisole was invented in 1966 in Belgium by Janssen Pharmaceuticals. It is on the World Health Organization's List of Essential Medicines. Levamisole is also used as a dewormer for cattle.